secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001759425-25-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum Q1 revenue $111.6M; raises 2025 guidance to $435-450M
-----------------------------------------------------------

- Q1 2025 total revenue $111.6M vs $69.2M YoY, driven by LIVMARLI ($73.2M, +71%) and Bile Acid Medicines ($38.4M, +47%).
- Raises full-year 2025 revenue guidance to $435-450M from prior range.
- LIVMARLI oral tablet formulation approved by FDA; also approved in Japan for ALGS and PFIC.
- VISTAS PSC study enrollment completion expected Q3 2025; topline data Q2 2026.
- Cash and investments $298.6M as of March 31, 2025, up from $292.8M at year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942525000030/0001759425-25-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942525000030/mirm-20250507.htm
  HTML page:      https://secwatch.observer/filing/0001759425-25-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer